Aarti Industries Ltd

- Management indicated that there will be additional debt funding over the next 2 years. - The capex underway will be partially funded through internal accruals and partially through debt. - Bank lines (including fund-based and non-fund-based) total upwards of INR 2,000 crore, with CC utilization around INR 1,400-1,500 crore. - No specific mention of equity fundraising in the call. - Debt repayments of roughly INR 350 crore are planned evenly spread across the quarters in FY '24. Summary: The company plans to raise additional debt to fund capex in the near term but has not indicated any equity fundraising currently or in the immediate future.

- Ongoing capex guidance for FY '24 and FY '25 is around INR 3,000 crore combined, with approximately INR 1,500 crore each year. - Capex includes expansions like Nitro chlorobenzene plant expansion (FY '24), Acid division capacity expansion (~22%), Ethylation plant capacity tripling, and Nitro Toluene debottlenecking (all targeted in FY '25). - Two specialty chemical process blocks commissioned recently, funded partly from the INR 607 crore downstream and specialty chemicals capex; these blocks expected to contribute both captive use and outside sales with ~25-30% EBITDA margin. - The expansions support volume growth for FY '24 and beyond. - Part of the capex is for asset maintenance and revamps, including opportunistic shutdowns for enhancements. - Capex partially funded by internal accruals and partially through additional debt.

- Volume growth guidance: ~25% in FY '24 with further 15-20% growth expected in FY '25. - EBITDA growth guidance: Around 15% in FY '24 and ~40% in FY '25 due to volume ramp-up and correction in nonregular market sales. - Capacity expansions contributing to growth: Nitro chlorobenzene plant (FY '24 completion), Acid division capacity (+22% in FY '25), ethylation plant tripling (FY '25), nitro toluene debottlenecking (FY '25). - Utilization of long-term contracts: Contract 1 expected to reach 30-50%, Contract 3 60-70% utilization by FY '25; Contract 2 remains flat. - New capacities and multipurpose plants commissioning: Zone 4 plants from FY '25, with major volume growth from FY '26 onwards. - Overall, business expected to grow faster long-term as utilization improves beyond the current ~30-50% to 70%.

- FY '24 volume growth guidance is around 25%, with EBITDA growth expected to be lower at about 15%, due to parts of volume going into lower-margin nonregular markets. - FY '25 volume growth anticipated at 15-20% with EBITDA expected to grow roughly 40%, driven by volume shifts back from nonregular markets and additional volume growth. - Long-term contract utilization expected to ramp up to 60-70% in FY '25. - Margin pressures in FY '24 due to elevated costs and partial nonregular market sales, with expected improvement in FY '25. - Strong pricing mechanisms in place to mitigate input cost volatility, protecting profitability. - Company targets INR 1,700 crore EBITDA for FY '25, maintaining 25% CAGR EBITDA growth guidance for FY '24 and FY '25. - Capex and capacity expansions ongoing to support volume and earnings growth. - Additional debt likely for capex funding over next two years.

The transcript does not explicitly provide details on the current or expected order book or pending orders. However, relevant insights include: - The company has three long-term contracts contributing to growth; Contract 3 commissioned in Q3 FY23, Contract 2 is flattish, and Contract 1 utilization is expected to increase from 20% to 30-50%. - Volume growth of 25% for FY24 is partly driven by ramp-up of these contracts alongside base business growth. - Demand trends indicate confidence in market share gains and volume growth continuing into FY24 and FY25. - The company is navigating inventory and working capital adjustments due to high-interest costs affecting customer supply chains. - Volume growth in FY23 was over 15%, with some shifts to nonregular markets (5-10% share). - Capex and working capital are partially debt-funded, indicating active order execution and capacity expansion. No specific numeric value for order book or pending orders is disclosed.